Immune-checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have transformed oncologic therapeutic modalities. By disrupting tumor-induced immunosuppression, ICIs facilitated effective treatment of numerous malignancies, including metastatic melanoma; however, due to the ensuing disturbance immune system, various immune-mediated adverse reactions been reported with ICI therapy. We p...